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infectious agents. More than 60 serotypes of enteroviruses
are classified into four groups: coxsackievirus A (CA), cox-
sackievirus B (CB), echovirus (Echo), poliovirus and new
enterovirus. While most enteroviral cases are either
asymptomatic or have mild symptoms (e.g., mild upper
respiratory problems), some cases exhibit symptoms such
as hand-foot-mouth disease (HFMD), herpangina, aseptic
encephalitis, viral meningitis and acute hemorrhagic
conjunctivitis. Severe complications have potentially lethal
consequences.1
EV71 was first isolated in California in 1969. In the 1970s,
two EV71 outbreaks caused a number of deaths in Bulgaria
and Hungary, but the enterovirus threat did not receive
much attention until epidemics erupted in Malaysia and
Taiwan in 1997 and 1998, respectively. Since then, HFMD
surveillance systems have been established successively in
Malaysia, Singapore, Thailand, China and Vietnam.
According to regional surveillance data, EV71 and CA16 are
the major pathogenic virus types for HFMD in the Southeast
Asian countries.2,3* Corresponding author. Centers for Disease Control, Department
of Health, 6, Linsen South Road, Taipei 10050, Taiwan.
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http://dx.doi.org/10.1016/j.jfma.2012.12.001Various surveillance systems were established in Taiwan
after the 1998 EV71 outbreak. First, the contracted viro-
logical laboratory system is responsible for enterovirus
isolation and the typing of clinical samples collected by
sentinel physicians. Second, physicians should report
enterovirus infections with severe complications as class C
diseases to the National Notifiable Surveillance System.
Third, the Real-time Outbreak and Disease Surveillance
System (RODS) replaced the physician-based Sentinel
Surveillance System for HFMD and herpangina in 2007. The
new system monitors enterovirus consultation trends in
hospital emergency rooms to provide timely surveillance
data. Fourth, syndromic surveillance through the National
Health Insurance Claims Database (NHICD) covering 99% of
outpatient, inpatient and emergency room visits in Taiwan
was established in April 2009. It collects the number of
visits for enterovirus infection to estimate disease burden.
Community virus surveillance statistics from Taiwan’s
virological contract laboratories indicate that CA is the
most prevalent serotype. Of these, CA16 is the most
common, and high isolation rates were seen in 2000e2003,
20054,5, 2007 and 2010. EV71 activity was high in 2000,
2001, 20054,5 and 2008. However, because 19e78% of virus
strains could not be identified by commercial immunofluo-
rescent kits in 2002e2006, Taiwan’s Centers for Disease
Control (TCDC) has developed several immunofluorescent
kits for detecting CA2, 4, 5, 6, 10 and 21 since 2005. These& Formosan Medical Association. All rights reserved.
Figure 1 Enterovirus infections with severe complications vs. isolation rate of CA, EV71 and CA16 in Taiwan, 2002-2011.
509new detection kits have reduced the number of unidenti-
fied viruses significantly.6
National Notifiable Surveillance System data show that,
although the majority of severe cases were infected by
EV71, other enteroviruses also caused severe complications
in newborns, including CB3 (in 1999, 2000 and 2005), Echo 4
and Echo 6 (in 2001). The distribution of enterovirus sero-
types isolated from severe cases from 1998 to 2011 were
EV71 (80.2%), CB3 (3.8%) and CA16 (1.3%). The distribution
of lethal cases were EV71 (76.0%), CB3 (3.4%) and Echo
6 (2.9%).
Fig. 1 illustrates trends from 2002 to 2011, based on data
from contracted virological laboratories and the national
notifiable disease surveillance system. It is clear that CA16
and EV71 were the most prevalent virus types, and the
trends of severe case numbers and isolation rate of EV71
are consistent. However, the epidemic cycle for EV71 was
irregular, ranging from 2e4 years. CA serogroups such as
CA6, CA10, CA4, CA5 and CA9 with low virulence were the
main epidemic strains in 2007 and 2009e2011 (data not
shown).
EV71 is clearly more virulent than other enteroviruses.1,7
Research to develop an EV71 vaccine has been actively
pursued in Taiwan, China and Singapore. Such vaccines are
in clinical trials in these countries and are expected to be
marketed within 5 to 10 years.7,8 However, CA2-8, 10, 12
and 14 can also cause HFMD,2 and the current vaccines do
not address this threat for several reasons. First, the rela-
tionship between severe cases and virus types shown in
Fig. 1 indicates that 80% of severe cases were caused by
EV71. Second, while it is true that including CA16 or other
CA serogroups in vaccine components can reduce the inci-
dence of HFMD, the experiments needed on cross-reactions
in bivalent or multivalent vaccines, is time-consuming, and
will delay the release of vaccines.
EV71 has only one serotype, but it can be further clas-
sified into three genogroups and 11 subgenotypes (A, B1eB5
and C1eC5). In Taiwan, various subgenotypes have been
isolated: C2/B4/C4 in 1998, B4 in 1999e2003, C4 in
2004e2005, C5 in 2006, C5/B5 in 2007, B5 in 2008e2009, C4
(closely related to the Chinese strain) in 2010 and C4/B5 in
2011. Surveillance data in Taiwan did not show a significant
relationship between the subgenotypes and CNS complica-
tions.8 This issue deserves further study, because whether
or not the neutralizing antibodies from differentsubgenotypes of EV71 can provide enough immunity
protection, is one of the critical factors for evaluating
vaccine candidates.1
In conclusion, the development of a monovalent vaccine
against EV71 obtains a much higher cost-benefit value than
a bivalent or multivalent vaccine, because EV71 is known to
be the major cause of severe enteroviral cases.9 Other
enteroviral serotypes, such as CB3, Echo 4 and Echo 6, may
also cause neonatal severe complication or deaths, but
their epidemic periods are uncertain and the disease
burden incurred on the public health system is currently
tolerable. Therefore, even though EV71 vaccine will be
available soon, systemic enterovirus surveillance and
development of diagnostic technology should be continued
and improved to monitor evolving serotypes, with the hope
of preventing enterovirus epidemics.
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